Algae source functional active peptide, preparation and application
By extracting and synthesizing FPRFR and FLF bioactive peptides from *Chlorella pseudocarpa*, the problems of poor protein stability and absorption difficulties of *Chlorella pseudocarpa* have been solved, leading to the development of foods, drugs, or health products with antioxidant and uric acid-lowering effects, thus improving safety and economic benefits.
Patent Information
- Application Number
- CN202511918323.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-18
- Publication Date
- 2026-03-13
AI Technical Summary
Micrococcus pseudospiral protein has poor stability and is not easily digested and absorbed by the human body, which limits its application in the fields of food, health care and medicine. Existing uric acid-lowering drugs have toxic side effects, so it is necessary to find safer alternatives.
Bioactive peptides with amino acid sequences FPRFR and FLF are extracted and synthesized from *Micrococcus pseudocarpa* and applied to food, pharmaceuticals, or health products. Utilizing their antioxidant and uric acid-lowering effects, formulations with a concentration of 1 mg/mL are prepared.
It provides natural and safe antioxidant and uric acid-lowering products, promotes the in-depth utilization of microalgae protein resources, and improves the safety and economic benefits of the products.
Smart Images

Figure CN121652229A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of bioactive peptide technology, specifically relating to an algal-derived functional active peptide, its formulation, and its uses. Background Technology
[0002] Micrococcus pseudocarpa protein is a functional protein found in algae, possessing uric acid-lowering and antioxidant properties. However, as a biological macromolecule, micrococcus pseudocarpa protein exhibits poor stability, is easily inactivated, and is not readily digested and absorbed by the human body. These characteristics limit its further application in the fields of food, health products, and medicine.
[0003] Gout is a metabolic disorder caused by excessively high levels of uric acid in the blood, severely impacting the quality of life for modern people. Its incidence is gradually increasing. Currently, the mechanisms of action of drugs used to treat gout include inhibiting uric acid production, promoting uric acid excretion, and breaking down uric acid. Xanthine oxidase (XO) is a key enzyme in the human body that catalyzes the conversion of hypoxanthine to xanthine, which in turn generates uric acid, or directly catalyzes the conversion of xanthine to uric acid. Therefore, the rate of uric acid production depends to some extent on the activity of XO. Currently, allopurinol and febuxostat are commonly used to inhibit XO activity, with relatively significant therapeutic effects. However, there is a risk of inducing gout attacks in the early stages of treatment, and certain toxic side effects exist. With increasing health awareness, finding drug alternatives with fewer toxic side effects has become a current research hotspot. Many natural products have been proven to have uric acid-lowering activity, such as flavonoids, phenolic acids, polysaccharides, and bioactive peptides. Among them, bioactive peptides have attracted much attention due to their low preparation cost, low sample cost, easy absorption, and high safety.
[0004] Bioactive peptides are specific protein fragments that have a positive impact on human health. Compared to intact proteins, small molecule peptide fragments have multiple advantages: they are more easily absorbed and utilized by the human body, have high activity, and can exert physiological effects even at low concentrations; their small molecular weight makes them easy to modify and synthesize, and they can be obtained through artificial chemical synthesis and other methods. Compared to single amino acids, small molecule peptides not only possess special physiological activities, but their absorption channels and rates also have unique advantages.
[0005] Therefore, developing bioactive peptides derived from *Micrococcus pseudocarpa* with uric acid-lowering and antioxidant activities has significant economic and social benefits. Summary of the Invention
[0006] In view of the problems existing in the prior art, the purpose of this invention is to provide an algal functional active peptide, preparation and use.
[0007] To achieve the above objectives, the present invention adopts the following technical solution: An algal-derived functional bioactive peptide, wherein the amino acid sequence of the algal-derived functional bioactive peptide is at least one of FPRFR and FLF.
[0008] The above-mentioned algal-derived functional active peptides are used in the preparation of products with antioxidant and uric acid-lowering effects.
[0009] Based on the above scheme, the product is food, medicine or health product.
[0010] Based on the above scheme, the product further includes excipients acceptable for food, pharmaceutical or health products.
[0011] Based on the above scheme, the antioxidant mentioned has a DPPH free radical scavenging effect.
[0012] Based on the above approach, the uric acid-lowering effect is achieved by increasing the XOD inhibition rate.
[0013] A preparation with antioxidant and uric acid-lowering effects, the active ingredient being at least one of FPRFR and FLF.
[0014] Based on the above scheme, the concentration of the active ingredient is 1 mg / mL.
[0015] Advantages of the technical solution of this invention: This invention uses *Micrococcus pseudochlorella* as raw material and employs methods such as protease hydrolysis, LC-MS / MS, and bioinformatics to isolate and purify two bioactive peptides with antioxidant and uric acid-lowering effects. Based on the identified peptide sequences, these peptides were chemically synthesized, and the uric acid-lowering and antioxidant effects of the synthesized single and compound peptides were measured. These bioactive peptides all exhibited good XOD inhibition and DPPH scavenging rates. Therefore, these algal-derived functional bioactive peptides can not only be used as natural antioxidants in food, pharmaceuticals, and / or cosmetics, but also as natural uric acid-lowering supplements in pharmaceuticals; they have significant application prospects in the development of products with uric acid-lowering and antioxidant effects.
[0016] This invention develops bioactive peptides with uric acid-lowering and antioxidant effects from *Chlorella pseudocarpa* protein. It can not only provide natural and safe uric acid-lowering and antioxidant products, but also promote the in-depth utilization of *Chlorella pseudocarpa* protein resources and industrial development, which is of great significance for promoting human health and economic development. Attached Figure Description
[0017] Figure 1 DPPH scavenging rate of enzymatic hydrolysis products with different molecular weights; Figure 2 XOD inhibition rate of enzymatic hydrolysis products with different molecular weights; Figure 3 This is the total ion chromatogram; Figure 4 This is a second-order mass spectrum of FPRFR; Figure 5This is a second-order mass spectrum of FLF; Figure 6 Effects of different proteases on the degree of hydrolysis of *Micrococcus pseudocarpa* proteins; Figure 7 Effects of different proteases on the DPPH scavenging rate of *Micrococcus pseudocarpa* protease hydrolysates; Figure 8 Effects of different proteases on the XOD inhibition rate of *Micrococcus pseudocarpa* proteolytic products; Figure 9 DPPH scavenging rates of single peptides and complex peptides; Figure 10 Inhibition rates of XOD by single peptides and complex peptides. Detailed Implementation
[0018] The terminology used in this invention, unless otherwise specified, generally has the meanings commonly understood by those skilled in the art. The invention is further described in detail below with reference to specific embodiments and data. The following embodiments are merely illustrative and are not intended to limit the scope of the invention in any way.
[0019] Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the experimental materials, reagents, and chemicals used in the following embodiments can be obtained through general channels.
[0020] In the following embodiments, 1. The method for determining the degree of hydrolysis is as follows: The degree of hydrolysis of *Chlorella pseudocarpa* protein was determined using the ophthaldialdehyde (OPA) method. The specific method is as follows: 80 mg of OPA was dissolved in a mixture of 2 mL anhydrous ethanol, 200 μL β-mercaptoethanol, 5 mL 10% SDS (w / v), and 92.8 mL 0.1 mol / L sodium tetraborate to prepare a 100 mL OPA reagent solution. 40 μL of the *Chlorella pseudocarpa* enzymatic hydrolysis product was mixed with 4 mL of OPA reagent and incubated at room temperature for 2 min, and the absorbance was measured at 340 nm. The *Chlorella pseudocarpa* protein was then placed in 6 mol / L HCl and reacted at 115 °C for 24 h. The number of free amino groups was determined using a serine standard curve, which was taken as the number of free amino acids produced by complete protein hydrolysis.
[0021] The degree of protein hydrolysis is calculated using the following formula: In the formula: (NH2) t Indicates the amount of free amino acids released; (NH2) t0Indicates the amount of free amino acids that have not undergone enzymatic hydrolysis; (NH2) T This indicates the number of free amino acids after complete hydrolysis.
[0022] 2. DPPH free radical scavenging rate determination Prepare a 0.1 mmol / L DPPH ethanol solution and store it in the dark. Dilute different molecular weight *Chlorella vulgaris* protein peptides with ethanol to concentrations of 50, 100, 200, 400, and 800 μg / mL. Mix 2 mL of the sample solution with 2 mL of DPPH solution and react in the dark for 30 minutes. Measure the absorbance at 517 nm. A control group (2 mL ethanol + 2 mL DPPH solution) and a blank group (2 mL sample solution + 2 mL ethanol) were also prepared.
[0023] Calculate the free radical scavenging rate using the following formula: In the formula: A control is the water-substituted sample group; A sample is the sample and DPPH group; A sample blank is the ethanol-substituted DPPH group.
[0024] 3. XOD inhibitory activity assay (1) Prepare xanthine solution (0.48mM), PBS buffer, xanthine oxidase solution and 1M HCl, as follows: Xanthine solution (0.48mM): Weigh 4.56mg of xanthine powder, dissolve it in 1000μL of 0.1mol / L NaOH, and bring the volume to 100mL with PBS buffer.
[0025] PBS buffer: Sodium dihydrogen phosphate solution: Weigh 3.12g of sodium dihydrogen phosphate and dilute to 400mL with ultrapure water. Disodium hydrogen phosphate solution: Weigh 7.16g of disodium hydrogen phosphate and dilute to 400mL with ultrapure water. Mix the above: Take 76mL of sodium dihydrogen phosphate solution and mix with 324mL of disodium hydrogen phosphate solution.
[0026] Xanthine oxidase solution: Weigh 1 mg of enzyme powder, add PBS buffer to a final volume of 10 mL, mix well, and store at -20°C.
[0027] 1M HCl: Used to terminate the reaction.
[0028] (2) Group A (sample group), Group B (no enzyme group), Group C (no sample group), and Group D (no enzyme and sample group) were set up respectively. The reagents and assay methods for each group are as follows: Group A (sample group): 25 μL sample solution + 25 μL xanthine oxidase solution, react at 25℃ for 10 min, then add 75 μL xanthine solution, react at 25℃ for 30 min, then add 50 μL 1M HCl to terminate the reaction, and measure the absorbance at 290 nm (denoted as A).
[0029] Group B (without enzyme): 25 μL sample solution + 25 μL PBS, react at 25℃ for 10 min, then add 75 μL xanthine solution, react at 25℃ for 25 min, then add 50 μL 1M HCl to stop the reaction, and measure the absorbance at 290 nm (denoted as B).
[0030] Group C (no sample added): 25 μL PBS + 25 μL xanthine oxidase solution, react at 25℃ for 10 min, then add 75 μL xanthine solution, react at 25℃ for 30 min, then add 50 μL 1M HCl to stop the reaction, and measure the absorbance at 290 nm (denoted as C).
[0031] Group D (without enzyme and sample): 50 μL PBS, react at 25℃ for 10 min, then add 75 μL xanthine solution, react at 25℃ for 10 min, then add 50 μL 1M HCl to stop the reaction, and measure the absorbance at 290 nm (denoted as D).
[0032] (3) Calculate the XOD inhibition rate according to the following formula: In the formula: A is the sample group; B is the group without enzyme; C is the group without sample; D is the sample group without enzyme.
[0033] In the following examples, the *Micrococcus pluvialis* powder was sourced from Shaanxi Guben Biotechnology Co., Ltd.
[0034] Example 1 A method for preparing an algal-derived functional active peptide, comprising the following steps: (1) Preparation of *Chlorella pseudomicrophylla* protein: Dissolve 20g of *Chlorella pseudomicrophylla* powder in 300mL of pure water and stir magnetically at 25℃ for 30 minutes. Then, perform freeze-thaw treatment: freeze at -20℃ for 80 minutes and thaw at 4℃, repeating three times. Then, sonicate at 100W power, with a 5-second interval between every 10 seconds of sonication, for a total of 300 times, using an ice bath throughout to prevent protein denaturation and to release the protein. Centrifuge the resulting solution at 4℃ and 8000r / min for 30 minutes, and collect the supernatant. Add an equal volume of 95% ethanol, shake to mix, centrifuge at 4℃ and 4000r / min for 10 minutes, discard the supernatant green layer, collect the precipitate, pre-freeze at -80℃ and then freeze-dry under vacuum to obtain *Chlorella pseudomicrophylla* protein powder for later use.
[0035] (2) Dissolve the *Chlorella pseudocaryophyllum* protein powder prepared in step (1) in ultrapure water at a ratio of 1:10. Adjust the pH of the solution to 10 using hydrochloric acid and sodium hydroxide. Add an alkaline protease with an enzyme activity of 200,000 U / g to the *Chlorella pseudocaryophyllum* protein solution. The amount of alkaline protease added is calculated based on the standard of adding 2,000 U of enzyme activity per gram of *Chlorella pseudocaryophyllum* protein, and the formula can be expressed as: Stir magnetically until homogeneous, then heat to 55℃ and incubate for 8 hours for enzymatic hydrolysis. After hydrolysis, incubate at 90℃ for 15 minutes to inactivate the enzyme, cool to 25℃ in an ice-water bath, and centrifuge at 4℃ and 6000 rpm for 20 minutes. Collect the supernatant to obtain the enzymatic hydrolysis product. Freeze-dry and store at -80℃.
[0036] (3) After filtering the supernatant obtained from the above enzymatic hydrolysis through a 0.45-micron filter membrane, the supernatant was fractionated into different molecular weights using an ultrafiltration centrifuge tube. The ultrafiltration separation conditions were 4000 g / min and centrifugation at 4 ℃ for 20 min, with molecular weight cutoffs of 10 kDa and 3 kDa. The fractions collected were as follows: >10 kDa, peptides were retained but did not pass through the 10 kDa membrane; 310 kDa, peptides permeated into the 10 kDa membrane but not into the 3 kDa membrane; <3 kDa, peptides permeated into the 3 kDa membrane. Thus, proteolytic hydrolysates with molecular weights ranging from <3 kDa to 10 kDa were obtained.
[0037] The antioxidant DPPH scavenging effect was determined for components with different molecular weights, and the results are as follows: Figure 1 As shown, proteins with smaller molecular weights (< 3 kDa) exhibit better antioxidant effects, with a DPPH scavenging rate of 87.63%, compared to 80.26% for 3-10 kDa and 69.1% for >10 kDa.
[0038] The XOD inhibitory activity of components with different molecular weights was determined, and the results are as follows: Figure 2 As shown, protein peptides with smaller molecular weights (< 3 kDa) exhibited better inhibitory effects on xanthine oxidase, with an XOD inhibition rate of 75.05%, 64% for 3-10 kDa, and 49.15% for >10 kDa.
[0039] (4) Identify the peptide sequences in protein peptides with a molecular weight < 3 kDa using LC-MS / MS. The liquid chromatography conditions were as follows: C18 analytical column (75 μm × 150 mm, 3 μm), flow rate 300 nL / min. Mobile phase A was 0.1% formic acid, 2% ACN; mobile phase B was 0.1% formic acid, 80% ACN; elution was performed with 6–9% B for 8 min, 9–14% B for 14 min, 14–30% B for 36 min, 30–40% B for 15 min, 40–95% B for 3 min, and 95% B held for 5 min.
[0040] Mass spectrometry conditions were: MSAS scan range (m / z) 100~1500, AGC target: 3e6; resolution: 70000, etc.
[0041] The total ion chromatogram of *Micrococcus pluvialis* protein peptides is shown below. Figure 3 As shown.
[0042] (5) Mass spectrometry data were retrieved from the Uniport database using MaxOuant software. Bioinformatics analysis was performed on the identified peptide sequences, including four core modules: basic physicochemical property analysis, post-translational modification (PTM) annotation, peptide activity potential prediction, and toxicity risk assessment. Peptide sequences with molecular weight <1000 Da and AREA <10 were screened. 7 After removing modified peptides and peptides with a score >0.6 (preferably >0.9), two bioactive peptides from *Chlorella vulgaris* were selected based on screening criteria and factors: FPRFR and FLF. These two peptides were then chemically synthesized, and their mass spectra are shown below. Figure 4 and Figure 5 As shown.
[0043] Example 2 Effects of different proteases on the proteolytic activity of Micrococcus pseudocarpa Enzymatic hydrolysis of *Microcystis aeruginosa* proteins by proteases is crucial. Different enzymes have different cleavage sites, producing different peptides that affect the hydrolysis efficiency and functional properties of the products, including the degree of protein hydrolysis and the bioactivity of the resulting peptides. The degree of hydrolysis of *Microcystis aeruginosa* proteins by two proteases (alkaline protease and neutral protease) was determined using the following steps: (1) Preparation of *Chlorella pseudomicrophylla* protein: Dissolve 20g of *Chlorella pseudomicrophylla* powder in 300mL of pure water and stir magnetically at 25℃ for 30 minutes. Then, perform freeze-thaw treatment: freeze at -20℃ for 80 minutes and thaw at 4℃, repeating three times. Then, sonicate at 100W power, with a 5-second interval between every 10 seconds of sonication, for a total of 300 times, using an ice bath throughout to prevent protein denaturation and to release the protein. Centrifuge the resulting solution at 4℃ and 8000r / min for 30 minutes, and collect the supernatant. Add an equal volume of 95% ethanol, shake to mix, centrifuge at 4℃ and 4000r / min for 10 minutes, discard the supernatant green layer, collect the precipitate, pre-freeze at -80℃ and then freeze-dry under vacuum to obtain *Chlorella pseudomicrophylla* protein powder for later use.
[0044] (2) Dissolve the *Micrococcus pluvialis* protein powder prepared in step (1) in ultrapure water at a ratio of 1:10. Add alkaline protease with an activity of 200,000 U / g and neutral protease with an activity of 50,000 U / g respectively. Adjust the pH of the solution with hydrochloric acid and sodium hydroxide to maintain the optimal pH of the protease. Stir magnetically until homogeneous, and enzymatically hydrolyze for 8 hours at the optimal temperature and optimal pH (Table 1) for each protease. After enzymatic hydrolysis, incubate at 90℃ for 15 minutes to inactivate the enzyme, cool to 25℃ in an ice-water bath, and centrifuge at 4℃ and 6000 r / min for 20 minutes. Take the supernatant to obtain the enzymatic hydrolysis product.
[0045] The effects of different proteases on the degree of hydrolysis of *Micrococcus pseudocarpa* proteins were determined, and the results are as follows: Figure 6 As shown.
[0046] Table 1 Optimal reaction conditions for different proteases The degree of protein hydrolysis is one of the important indicators for evaluating the high biological activity of enzymatic hydrolysates; better hydrolysis releases more active groups. Figure 6 It can be seen that the degree of hydrolysis of *Micrococcus pseudocarpa* protein by alkaline protease and neutral protease is 32.5% and 26.95%, respectively. Compared with neutral protease, alkaline protease has a higher degree of hydrolysis of *Micrococcus pseudocarpa* protein.
[0047] The DPPH scavenging rate of *Micrococcus pseudocarpa* protease hydrolysates obtained using different proteases was determined, and the results are as follows: Figure 7 As shown, the DPPH scavenging rate of the enzymatic hydrolysate obtained after alkaline protease hydrolysis was 48.15%, while that of neutral protease was 39.55%. The antioxidant effect of the enzymatic hydrolysate obtained after alkaline protease hydrolysis was higher than that of neutral protease. This may be because alkaline protease has higher activity in an alkaline environment, can more thoroughly hydrolyze proteins, and generate more antioxidant peptides containing hydrophobic amino acids and active groups; while neutral protease has a lower degree of hydrolysis, resulting in fewer active peptides and less exposure of active groups.
[0048] The XOD inhibitory activity of *Micrococcus pseudocarpa* protease hydrolysates obtained using different proteases was determined, and the results are as follows: Figure 8 As shown, the XOD activity of the samples after alkaline protease digestion was higher than that of neutral protease, at 52.45%, while that of neutral protease was 35.6%. This may be because the alkaline protease digestion products may have generated more peptides (such as peptides containing specific amino acid sequences or active groups) that can bind to xanthine oxidase (XOD) and inhibit its activity; while the neutral protease digestion products have a weaker inhibitory effect on XOD structurally, resulting in a lower inhibition rate.
[0049] Example 3 An algal-derived functional bioactive peptide, wherein the bioactive peptide is at least one of the peptide segments of the amino acid sequences shown in SEQ ID NO:1 and SEQ ID NO:2.
[0050] SEQ ID NO:1: FPRFR; SEQ ID NO:2: FLF.
[0051] Example 4 A bioactive peptide preparation with antioxidant and uric acid-lowering effects, the active ingredient being at least one of FPRFR and FLF active peptides.
[0052] Using pure water as a solvent, solutions of single peptides FPRFR, FLF, and the complex peptide FPRFR+FLF were prepared with a concentration of 1 mg / mL. In the complex peptide solution, the volume ratio of the two peptides was 1:1, and the concentration of each peptide was 1 mg / mL. The DPPH scavenging rate of the single peptide FPRFR, FLF solutions and the FPRFR+FLF complex peptide solution was determined. The results are as follows: Figure 9 As shown, the single synthetic peptide FPRFR: 52.15%, FLF: 40.65%, and the complex peptide FPRFR+FLF: 63%. The DPPH clearance rate of the FPRFR+FLF complex peptide solution was better than that of the single peptide solution.
[0053] The ability to determine the XOD inhibition rate of single peptide FPRFR, FLF, and the complex peptide FPRFR+FLF solution was studied. Results are as follows: Figure 10 As shown, the single synthetic peptide FPRFR was 66.06% and FLF was 62.36%, while the complex peptide FPRFR+FLF was 53.66%. Regarding the inhibition rate of XOD, the synthetic peptide from *Micrococcus pseudocarpa* showed better activity than the complex peptide. There was a certain weakening relationship among the complex peptides, with the single synthetic peptide FPRFR showing the best inhibition rate at 66.06%.
[0054] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention in any other way. Any person skilled in the art may make changes or modifications to the above-disclosed technical content to create equivalent embodiments. However, any simple modifications, equivalent changes, and modifications made to the above embodiments based on the technical essence of the present invention without departing from the scope of the present invention shall still fall within the protection scope of the present invention.
Claims
1. An algal-derived functional bioactive peptide, characterized in that, The amino acid sequence of the algal-derived functional active peptide is at least one of FPRFR and FLF.
2. The use of the algal-derived functional active peptides in claim 1 in the preparation of products with antioxidant and uric acid-lowering effects.
3. The application according to claim 2, characterized in that, The products mentioned are food, medicine, or health products.
4. The application according to claim 3, characterized in that, The product further includes food, pharmaceutical or health food-grade excipients.
5. The application according to claim 2, characterized in that, The antioxidant described herein has a DPPH free radical scavenging effect.
6. The application according to claim 2, characterized in that, It exerts its uric acid-lowering effect by increasing the XOD inhibition rate.
7. A preparation with antioxidant and uric acid-lowering effects, characterized in that, The active ingredient is at least one of FPRFR and FLF.
8. The preparation with antioxidant and uric acid-lowering effects according to claim 7, characterized in that, The concentration of the active ingredient is 1 mg / mL.
